MedTrace Logo

CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer

NCT05652569 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2026-01-28

No results posted yet for this study

Summary

CATCH is an indication-specific diagnostic platform, which drives the implementation of integrative, genomic profiling for metastatic breast cancer into the clinics. The main objective of this approach is to identify biomarkers and drug targets to guide targeted therapeutic interventions.

Eligible are all metastatic breast cancer patients (independent of gender), irrespective of molecular subtype.

At initial diagnosis of distant metastasis or progress at disease progression, biopsy samples from a prognostic-relevant metastasis are retrieved during standard-of-care procedures for central analyses, together with blood samples. In parallel to all standard-diagnostic measures, genomic and transcriptomic profiling is conducted to infer the underlying biology of the disease and identify patients who might profit from biomarker-guided interventions in clinical trials.

Samples not required for standard-of-care clinical procedures or genomic profiling are systematically collected in a dedicated bio-repository to fuel translational scientific companion programs. The continuously growing comprehensive database serves as an integrative resource for systematic, prospective multidimensional data collection (clinical records, biomaterial, genomic data).

In summary, the overarching goal is to generate a precision oncology platform to i) identify clinically-actionable biomarkers and drug targets that drive genomics-guided therapies and ii) couple the observational, diagnostic registry platform to an increasing number of independent, biomarker-stratified clinical therapy trials (CATCH-GUIDE).

Conditions

Interventions

OTHER

Genomic Profiling / Sequencing

Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) on metastatic biopsy lesions

Sponsors & Collaborators

  • University Hospital Heidelberg

    collaborator OTHER

  • German Cancer Research Center

    lead OTHER

Principal Investigators

  • Andreas Schneeweiss, MD · National Center for Tumor Diseases, Heidelberg

  • Peter Lichter, PhD · German Cancer Research Center

  • Verena Thewes, PhD · National Center for Tumor Diseases, Heidelberg

Eligibility

Min Age
14 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-12
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05652569 on ClinicalTrials.gov